Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711153 | 0.90 | GPBAR1 (0.38) | PARP1GPBAR1PDE3BPDE3AHTR1A | |
| SCHEMBL4596606 | 0.87 | MAOA (0.39) | PARP1GPBAR1HTR1AMAOAMAOB | |
| SCHEMBL4597053 | 0.87 | GPBAR1 (0.36) | PARP1GPBAR1HTR1AMAOAMAOB | |
| SCHEMBL4712612 | 0.86 | GRM2 (0.39) | PARP1GPBAR1PDE3BPDE3AGRM2 | |
| SCHEMBL4596891 | 0.86 | THRB (0.39) | GPBAR1HTR1AHTR7MAOAMAOB | |
| SCHEMBL4759415 | 0.86 | PARP1 (0.39) | PARP1GPBAR1PDE3BPDE3AMAOA | |
| SCHEMBL4597087 | 0.85 | GPBAR1 (0.34) | GPBAR1PDE3BPDE3AHTR1AHTR7 | |
| SCHEMBL4597121 | 0.84 | GPBAR1 (0.39) | GPBAR1PDE3BPDE3A | |
| SCHEMBL4709866 | 0.82 | PARP1 (0.39) | PARP1HTR1AHTR7GRM2 | |
| SCHEMBL4710012 | 0.82 | GPBAR1 (0.38) | PARP1GPBAR1HTR1AHTR7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |